Precigen vs Verastem
PGEN and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PGEN and VSTM compare
Precigen is the larger company, worth 2.3 times as much as Verastem ($1.5B against $671M).
Verastem scores higher on the StockData Score (3 against 2 for Precigen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PGEN | VSTM |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $671M |
| Share price | $4.29 | $7.41 |
| Change, 1 year | −11.5% | −1.9% |
| Change, 5 years | 11.1% | −77.0% |
| Beta (5Y) | 1.20 | 2.66 |
| Employees | 20 | 102 |
| StockData Score | ||
| Total score | 2 | 3 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 7.7× |
| P/B | 35.2× | 13.4× (better) |
| FCF yield | −7.5% | – |
| Growth | ||
| Revenue growth, 5Y average | −21.3% | −19.0% (better) |
| Profitability | ||
| Operating margin | – | −183% |
| Net margin | – | −232% |
| Return on equity | −4640% | −471% (better) |
| Financial health | ||
| Debt / equity | 2.15 | – |
| Interest coverage | – | −108.3× |
| Current ratio | 4.58 (better) | 2.25 |
| Altman Z-score | −11.14 | −7.37 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.2% | 109% |
| Held by insiders | 44.9% | 1.8% |
| Insider net buying, 12 months | −$32.5M | −$816K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 22.8% | 22.1% |
Go deeper
- PGEN stock overview
- PGEN income statement
- PGEN valuation and score
- VSTM stock overview
- VSTM income statement
- VSTM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.